Background
People living with HIV (PWH) face an increased risk of cardiovascular disease (CVD) that cannot be fully explained by traditional risk factors. Viral antigens, such as the HIV-1 envelope subunit glycoprotein (gp120), have been shown to persist in plasma even when viral load is suppressed, and may directly contribute to vascular inflammation and CVD. The pericoronary fat attenuation index (PFAI), which measures the computed tomography attenuation of pericoronary adipose tissue, has emerged as a robust, non-invasive biomarker that predicts overt cardiovascular disease. We hypothesized that in presence of gp120, PFAI would show increased peri-coronary inflammation.
Methods
We included participants from the Canadian HIV and Aging Cohort Study who had an undetectable viral load, measurements for plasma soluble gp120 (sgp120), and cardiac computed tomography angiography (CCTA). Sgp120 was measured by an in-house ELISA. We obtained PFAI by calculating the mean attenuation of all fat voxels (defined as those with an attenuation between -190 and -30 Hounsfield units [HU]) located within a radial distance from the outer vessel wall equal to the vessel’s diameter, in the segment of the right coronary artery situated 10 to 50 mm from the ostium. Higher values (closer to -30 HU) indicate more pericoronary inflammation and increased CVD risk. Data on all traditional and HIV-related risk factors were extracted from the central database. We developed multivariable linear regression models to assess the adjusted association between sgp120 and PFAI.
Results
Among 145 participants (14 women, 131 men), with a mean age of 56, 102 (77%) were current or former smokers, 13 (9%) had diabetes, 45 (31%) had high blood pressure, and 94 (65%) had detectable CVD on CCTA. All had undetectable viral loads, with a mean CD4 count of 628 cells/µL. Nadir CD4 was below 200 cells/µL in 68 (47%), and the mean duration of HIV infection was 19 years. Presence of CVD on CCTA was associated with higher PFAI (-77 HU vs -81 HU, p=0.028). Soluble gp120 was detectable in 65 (45%) participants and was associated with higher PFAI (-77 HU vs -80 HU, p=0.037). After adjusting for confounders, each log2 increase in sgp120 was associated with a predicted mean increase in PFAI of 0.35 (95% CI [0.004-0.71], p=0.047).
Conclusions
Our data support the hypothesis that sgp120, even during suppressive antiretroviral therapy, contributes to CVD in PWH. Residual viral products may represent a novel treatment target to reduce comorbidity in PWH.